Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions
| Autor: | Thomas Pizzoferrato, Anne B. Morris, Anthony E. Zimmermann, Robert Hoffman, John Bedford, Gregory Braden |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Microbiology (medical)
Male medicine.medical_specialty Anti-HIV Agents Organophosphonates Renal function Lopinavir/ritonavir Gastroenterology immune system diseases Risk Factors Internal medicine medicine Humans Drug Interactions Renal Insufficiency Tenofovir Didanosine Acute tubular necrosis Aged business.industry Adenine virus diseases Fanconi syndrome Middle Aged medicine.disease Atazanavir Infectious Diseases Endocrinology Creatinine Ritonavir business Kidney disease medicine.drug |
| Zdroj: | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 42(2) |
| ISSN: | 1537-6591 |
| Popis: | Tenofovir therapy in patients with human immunodeficiency virus (HIV) infection has been associated with acute renal failure (ARF) and Fanconi syndrome. In the past 2 years, we diagnosed tenofovir-associated ARF in 5 HIV-infected patients who were receiving tenofovir therapy and who had classic findings of acute tubular necrosis, and we compared findings for our patients with data on 22 patients described in the literature. The mean serum creatinine level increased from 0.9 to 3.9 mg/dL, and it decreased to 1.2 mg/dL during recovery. ARF resolved in 22 of 27 patients after discontinuation of tenofovir therapy. The most common drugs given with tenofovir were ritonavir or lopinavir-ritonavir (21 of 27 patients), atazanavir (5 of 27 patients), and didanosine (9 of 27 patients). Tenofovir-associated ARF manifests as acute tubular necrosis that may not resolve with tenofovir withdrawal. Tenofovir is associated with multiple drug interactions, leading to an increased risk of ARF. Frequent monitoring of renal function is warranted for any patient receiving these combinations. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|